IBDEI2M2 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,43823,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,43823,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,43823,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,43824,0)
 ;;=L50.9^^200^2217^286
 ;;^UTILITY(U,$J,358.3,43824,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43824,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,43824,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,43824,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,43825,0)
 ;;=L53.8^^200^2217^147
 ;;^UTILITY(U,$J,358.3,43825,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43825,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,43825,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,43825,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,43826,0)
 ;;=L53.9^^200^2217^146
 ;;^UTILITY(U,$J,358.3,43826,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43826,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,43826,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,43826,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,43827,0)
 ;;=L54.^^200^2217^145
 ;;^UTILITY(U,$J,358.3,43827,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43827,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,43827,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,43827,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,43828,0)
 ;;=L56.0^^200^2217^139
 ;;^UTILITY(U,$J,358.3,43828,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43828,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,43828,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,43828,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,43829,0)
 ;;=L56.1^^200^2217^138
 ;;^UTILITY(U,$J,358.3,43829,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43829,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,43829,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,43829,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,43830,0)
 ;;=L56.2^^200^2217^236
 ;;^UTILITY(U,$J,358.3,43830,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43830,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,43830,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,43830,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,43831,0)
 ;;=L56.3^^200^2217^268
 ;;^UTILITY(U,$J,358.3,43831,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43831,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,43831,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,43831,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,43832,0)
 ;;=L57.0^^200^2217^12
 ;;^UTILITY(U,$J,358.3,43832,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43832,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,43832,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,43832,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,43833,0)
 ;;=L60.0^^200^2217^161
 ;;^UTILITY(U,$J,358.3,43833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43833,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,43833,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,43833,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,43834,0)
 ;;=L60.1^^200^2217^234
 ;;^UTILITY(U,$J,358.3,43834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43834,1,3,0)
 ;;=3^Onycholysis
 ;;^UTILITY(U,$J,358.3,43834,1,4,0)
 ;;=4^L60.1
 ;;^UTILITY(U,$J,358.3,43834,2)
 ;;=^186837
 ;;^UTILITY(U,$J,358.3,43835,0)
 ;;=L60.2^^200^2217^233
 ;;^UTILITY(U,$J,358.3,43835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43835,1,3,0)
 ;;=3^Onychogryphosis
 ;;^UTILITY(U,$J,358.3,43835,1,4,0)
 ;;=4^L60.2
 ;;^UTILITY(U,$J,358.3,43835,2)
 ;;=^5009235
 ;;^UTILITY(U,$J,358.3,43836,0)
 ;;=L60.3^^200^2217^170
 ;;^UTILITY(U,$J,358.3,43836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43836,1,3,0)
 ;;=3^Nail Dystrophy
 ;;^UTILITY(U,$J,358.3,43836,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,43836,2)
 ;;=^5009236
